Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 17/20 | 0.47 |
| ▸ | F2 | P00734 | 11/20 | 0.47 |
| ▸ | F10 | P00742 | 10/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 10/20 | 0.47 |
| ▸ | F3 | P13726 | 5/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.46 |
| ▸ | KLK1 | P06870 | 1/20 | 0.31 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.31 |
| ▸ | F9 | P00740 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914847 | 0.90 | F7 (0.59) | F7F2F10PRSS1F3 | |
| Trifluoroacetic Acid SCHEMBL4903571 | 0.90 | F7 (0.50) | F7F2F10PRSS1F3 | |
| SCHEMBL13162226 | 0.88 | F7 (0.54) | F7F2F10PRSS1F3 | |
| SCHEMBL3463929 | 0.87 | F7 (0.53) | F7F2F10PRSS1F3 | |
| SCHEMBL3463461 | 0.86 | F7 (0.54) | F7F2F10PRSS1F3 | |
| SCHEMBL3463526 | 0.86 | F7 (0.54) | F7F2F10PRSS1F3 | |
| SCHEMBL3464697 | 0.86 | F7 (0.56) | F7F2F10PRSS1F3 | |
| SCHEMBL3464246 | 0.86 | F7 (0.60) | F7F2F10PRSS1F3 | |
| SCHEMBL3463229 | 0.85 | F7 (0.51) | F7F2F10PRSS1F3 | |
| SCHEMBL3463827 | 0.84 | F7 (0.44) | F7F2F10PRSS1F3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080132507-A1 | Hydrazide Derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2008-06-05 | — | — | US | disclosed |
| EP-1810965-A1 | HYDRAZIDE DERIVATIVES | Eisai R&D Management Co., Ltd. (JP) | 2007-07-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132507-A1 | Hydrazide Derivatives | H1-10, H1-4, H1-3 | F7 185/4885F2 19/4885F10 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.